LOS ALTOS, Calif. - RenovoRx Inc. (NASDAQ: RNXT), a biopharmaceutical company specializing in precision oncology therapies, has recently secured $6.1 million in private placement funding, which is set to extend its financial runway and support the progression of its pivotal Phase III TIGeR-PaC clinical trial. The trial is focused on locally advanced pancreatic cancer (LAPC) and is expected to reach a second interim analysis by the end of 2024.
The TIGeR-PaC study is a randomized multi-center trial that evaluates the efficacy of RenovoRx's lead product candidate, RenovoGem™, which employs the company's Trans-Arterial Micro-Perfusion (TAMP™) technology. This novel approach combines TAMP with the FDA-approved cancer drug, gemcitabine, and is being compared to the standard systemic intravenous chemotherapy.
A first interim analysis was completed in March 2023, which resulted in the Data Monitoring Committee recommending the continuation of the study. The primary endpoint of the TIGeR-PaC study is a 6-month Overall Survival benefit, with secondary endpoints including reduced side effects compared to the standard of care. These findings were presented at the 2023 American Association for Cancer Research Annual Meeting and the 2023 European Society of Medical Oncology World Congress on Gastrointestinal Cancer.
In addition to the trial's progress, RenovoRx has expanded its management team, Board of Directors, and Scientific Advisory Board, enhancing leadership and expertise. The company also filed an international patent application in December 2023 under the Patent Cooperation Treaty for its TAMP therapy platform, aiming to broaden its intellectual property portfolio and commercial potential.
RenovoRx's collaboration with Imugene, announced in July 2023, aims to explore the expansion of the TAMP product pipeline with CF33 oncolytic virus therapy for the treatment of difficult-to-access tumors. This collaboration, among others, could lead to potential out-licenses of RenovoGem as the company prepares for a New Drug Application filing, assuming successful study endpoints, and subsequent FDA approval.
This article is based on a press release statement from RenovoRx, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.